In TIOSPIR, 17,135 patients with COPD were randomized and treated in a double-blind, parallel-group, event-driven trial with follow-up of 2–3 years. Patients were randomized to once-daily tiotropium Respimat 5 or 2.5 μg, or once-daily tiotropium HandiHaler 18 μg (both Boehringer Ingelheim, Ingelheim am Rhein, Germany). The trial design and methodology have been published previously.13 (link) TIOSPIR was performed in accordance with the provisions of the Declaration of Helsinki, and the study protocol and procedures were approved by relevant institutional review boards and ethics committees (independent ethics committee Johns Hopkins Medicine Institutional Review Board, Baltimore, MD, USA). All the patients provided written informed consent.
Protocol detail
TIOSPIR: Tiotropium Respimat vs HandiHaler
Partial Protocol Preview
This section provides a glimpse into the protocol.
The remaining content is hidden due to licensing restrictions, but the full text is available at the following link:
Access Free Full Text.
Corresponding Organization :
Other organizations : University of Liverpool, Boehringer Ingelheim (Germany), Université Paris Cité, Hôpital Cochin, Sorbonne Paris Cité, South Texas Veterans Health Care System
Top 5 similar protocols
Protocol cited in 1 other protocol
Variable analysis
independent variables
- Once-daily tiotropium Respimat 5 μg
- Once-daily tiotropium Respimat 2.5 μg
- Once-daily tiotropium HandiHaler 18 μg
- Not explicitly mentioned
- Not explicitly mentioned
- No positive or negative controls were explicitly mentioned.
Annotations
Based on most similar protocols
Etiam vel ipsum. Morbi facilisis vestibulum nisl. Praesent cursus laoreet felis. Integer adipiscing pretium orci. Nulla facilisi. Quisque posuere bibendum purus. Nulla quam mauris, cursus eget, convallis ac, molestie non, enim. Aliquam congue. Quisque sagittis nonummy sapien. Proin molestie sem vitae urna. Maecenas lorem.
Sign up for free or login to display all annotations
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!